Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A view of the Novo Nordisk logo at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on March 8, 2024.
Tom Little | Reuters
Shares Novo Nordisk The Danish pharmaceutical giant jumped on Friday after reporting positive early-stage results for its weekly obesity drug amycretin.
The trial showed that the treatment, which is administered by injection, reduced the average weight by 22% after 36 weeks. That compares to a 2.0% weight gain in placebo-treated patients over the same time period.
The stock was 7.13% higher, matching gains of nearly 14%, but still recording its best single-session session since March 2024.
Shares of fellow Danish drug makers Zeeland Pharma Next up, it rose 4.7%, while Zepbound-Maker Eli Lilly has plunged into the premarket trade.
Amycretin targets the same GUT hormone GUGOVY mimics, known as GLP-1, as well as the hunger-inducing pancreatic hormone Amylin. Wegovy is Novo Nordisk’s obesity drug, as the Olympic is to treat its diabetes.
The trial was conducted in 125 overweight or obese patients and the most common side effects were gastrointestinal, with the majority being “moderate in severity”.
“We are very encouraged by the subcutaneous stages for 1B / 2A people who are overweight or obese.
“The results seen in the trial do not have GLP-1 and Amycretin amycretin amycretina, amycretin, amycretina, which we have previously seen with the oral formulation.”
Novo is also developing the amycretin obesity pill. Early stage testing In September, a 13.1% weight loss was announced after 12 weeks. The company said the treatment was safe and tolerable for patients, but side effects were moderate.
